Homology Medicines (LSE:0T6G) - Stock Price, News & Analysis

0T6G Stock Overview

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States.

About the company

0T6G fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue ($1M)

+ 1 more risk

Homology Medicines, Inc. Competitors

Arecor Therapeutics

AIM:AREC

UK£42.1m

Tissue Regenix Group

AIM:TRX

UK£43.3m

OptiBiotix Health

AIM:OPTI

UK£18.9m

Oncimmune Holdings

AIM:ONC

UK£17.1m

Price History & Performance

Summary of all time highs, changes and price drops for Homology Medicines
Historical stock prices
Current Share Price	US$0.97
52 Week High	US$1.40
52 Week Low	US$0.46
Beta	-0.11
1 Month Change	13.12%
3 Month Change	69.28%
1 Year Change	6.71%
3 Year Change	-90.70%
5 Year Change	-99.95%
Change since IPO	-95.56%

Recent updates

Shareholder Returns

	0T6G	GB Biotechs	GB Market
7D	8.7%	1.1%	1.2%
1Y	6.7%	-29.7%	-0.3%

Return vs Industry: 0T6G exceeded the UK Biotechs industry which returned -29.8% over the past year.

Return vs Market: 0T6G exceeded the UK Market which returned 3.8% over the past year.

Price Volatility

Is 0T6G's price volatile compared to industry and market?
0T6G volatility
0T6G Average Weekly Movement	11.3%
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.4%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0T6G's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 0T6G's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	7	n/a	www.homologymedicines.com

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies.

Homology Medicines, Inc. Fundamentals Summary

How do Homology Medicines's earnings and revenue compare to its market cap?
0T6G fundamental statistics
Market cap	US$54.34m
Earnings (TTM)	-US$112.96m
Revenue (TTM)	US$1.16m

47.0x

P/S Ratio

-0.5x

P/E Ratio

Is 0T6G overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0T6G income statement (TTM)
Revenue	US$1.16m
Cost of Revenue	US$62.00m
Gross Profit	-US$60.85m
Other Expenses	US$52.12m
Earnings	-US$112.96m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-34.98
Gross Margin	-5,263.49%
Net Profit Margin	-9,771.71%
Debt/Equity Ratio	0%

How did 0T6G perform over the long term?

See historical performance and comparison

0T6G Stock Overview

Rewards

Risk Analysis

Homology Medicines, Inc. Competitors

AIM:AREC

UK£42.1m

AIM:TRX

UK£43.3m

AIM:OPTI

UK£18.9m

AIM:ONC

UK£17.1m

Price History & Performance

Recent News & Updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Third quarter 2023 earnings released: US$0.57 loss per share (vs US$0.59 loss in 3Q 2022)

Recent updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Third quarter 2023 earnings released: US$0.57 loss per share (vs US$0.59 loss in 3Q 2022)

Homology Medicines, Inc. Approves Reduction in Workforce

New major risk - Revenue and earnings growth

Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting

First quarter 2023 earnings released: US$0.50 loss per share (vs US$1.61 profit in 1Q 2022)

Full year 2022 earnings released: US$0.087 loss per share (vs US$1.73 loss in FY 2021)

Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials

No longer forecast to breakeven

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Insufficient new directors

Insufficient new directors

Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer

Forecast to breakeven in 2022

First half 2022 earnings released: EPS: US$1.10 (vs US$0.56 loss in 1H 2021)

Homology Medicines Announces Optimized, in Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

Insufficient new directors

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2000 Dynamic Index

Homology Medicines, Inc. Announces FDA Lifted Clinical Hold on Phenix Gene Therapy Trial for Pku

First quarter 2022 earnings released: EPS: US$1.61 (vs US$0.021 loss in 1Q 2021)

Robbins Geller Rudman & Dowd LLP Announces That Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Homology Medicines, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Homology Medicines, Inc. Announces Promotion of Albert Seymour to President

Homology Medicines, Inc. Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU

Homology Medicines Announces Multiple Presentations on HMI-203 Gene Therapy Candidate for the Treatment of Hunter Syndrome

Insufficient new directors

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.62 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.54 loss per share (vs US$0.78 loss in 2Q 2020)

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2500 Growth Index

Homology Medicines, Inc. Announces Presentations on Its Expanding Genetic Medicines Platform and Internal GMP Manufacturing

First quarter 2021 earnings released: US$0.021 loss per share (vs US$0.78 loss in 1Q 2020)

Full year 2020 earnings released: US$2.80 loss per share (vs US$2.47 loss in FY 2019)

Revenue misses expectations

Novartis Elects to Terminate the Collaboration and License Agreement with Homology Medicines, Inc

Homology Medicines, Inc. Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (Pku) and Hunter Syndrome (Mps Ii)

Homology Medicines, Inc. announced that it expects to receive $60 million in funding from Pfizer Inc.

Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from S&P Biotechnology Select Industry Index

Shareholder Returns

Price Volatility

About the Company

Homology Medicines, Inc. Fundamentals Summary

47.0x

-0.5x

Earnings & Revenue